MEBO is a complex condition and while some of the cases seem simpler, non-linear analysis approaches are better equipped to handle the task. And this creates new challenges regarding the existence of confounding factors.
We are very close to concluding our clinical trial NCT03582826 according to the pre-specified protocol.
Recruitment to our microbiome study commenced in June 2018 and completed in December of 2018. The last batch of raw FASTQ sequences and raw taxonomy-level abundance summaries was received in October 2019. We had to spend more time on collecting and processing annotation data, ensuring quality, completeness, consistency and validity, and defining best approaches of dealing with"missing values".
We have now completed final data collection for the primary and secondary outcome measures.
The Anna Karenina principle (AKP), in the context of metabolic disorders, means that an uncompensated deficiency in any one of important enzymes, or presence of any one of pathogenic microorganisms, dooms the person to having the MEBO/PATM symptoms.